News
Ionis deal delivers for GSK as HBV drug hits the mark in pha...
An antisense drug developed by GlaxoSmithKline has been shown to suppress the hepatitis B virus (HBV) in a phase 2 trial, raising hopes of a “functional cure” for the widesprea
